Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials

[1] Shehabi Y(2014)Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial Am J Respir Crit Care Med 190 1102-1110

[2] Sterba M(2017)Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016 Intensive Care Med 43 304-377

[3] Garrett PM(2009)Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock Chest 136 1237-1248

[4] Rachakonda KS(2017)Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin MOnitoring SEpsis (MOSES) study Crit Care Med 45 781-789

[5] Stephens D(2013)Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis Lancet Infect Dis 13 426-435

[6] Harrigan P(2013)Promising new assays and technologies for the diagnosis and management of infectious diseases Clin Infect Dis 56 996-1002

[7] Walker A(2016)Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial JAMA Intern Med 176 1266-1276

[8] Bailey MJ(2010)Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial Lancet 375 463-474

[9] Johnson B(2016)Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial Lancet Infect Dis 16 819-827

[10] Millis D(2013)Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting Diagn Microbiol Infect Dis 76 266-271

[1] Shehabi Y(2014)Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial Am J Respir Crit Care Med 190 1102-1110

[2] Sterba M(2017)Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016 Intensive Care Med 43 304-377

[3] Garrett PM(2009)Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock Chest 136 1237-1248

[4] Rachakonda KS(2017)Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin MOnitoring SEpsis (MOSES) study Crit Care Med 45 781-789

[5] Stephens D(2013)Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis Lancet Infect Dis 13 426-435

[6] Harrigan P(2013)Promising new assays and technologies for the diagnosis and management of infectious diseases Clin Infect Dis 56 996-1002

[7] Walker A(2016)Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial JAMA Intern Med 176 1266-1276

[8] Bailey MJ(2010)Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial Lancet 375 463-474

[9] Johnson B(2016)Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial Lancet Infect Dis 16 819-827

[10] Millis D(2013)Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting Diagn Microbiol Infect Dis 76 266-271